Date closed: 12/4/2018
Value: C$87 million
On Decemeber 4, 2017, Resverlogix Corp. (Resverlogix) (TSX:RVX) announced the closing of a private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (Hepalink ) at a price of $1.44 per unit for gross proceeds of $87 million. Each unit was comprised of one common share and 0.082759 of a common share purchase warrant. Each full warrant is exercisable at a price of $1.64 per share for a period of four years from the closing of the offering.
Resverlogix, headquartered in Calgary, Alberta, is a biotechnology company, developing an epigenetic drug for the treatment of high-risk cardiovascular disease patients.
BLG represented Resverlogix led by Lloyd McLellan.
